July #37 : Off the Shelf - by Staff

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join

Back to home » Archives » POZ Magazine issues

Table of Contents

The Good Doctor

Dying for a Vaccine

Ashok to the System

Banking on Disaster

International Dream Team 1998

Not Your Average Joe


To the Editor

Conference Call

Poz Picks

AIDS Is Over

Mourning Star


Penny Wose, Pound Foolish

River Runs Dry

In the Blood

Nine Lives

Off the Shelf

Power Nutrients

Saved by the Cell

Time Warp

Catch Air!

Urine Luck

External Affairs

HIV, Sir!

Phone Sex

Germs in Sperm

Autograph Book

Baby Dolls

No Needles

Strike a Pose

CPR for HAART Failure

Salvadoran Savior

POZ Index

Indelicate Balance

Mistruths and Consequences

Positive Planet

Most Popular Lessons

The HIV Life Cycle


Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

email print

July 1998

Off the Shelf

by Staff

Protease + Hismanal = Trouble

With hay fever sneezin’ here, allergy sufferers on protease inhibitors beware: Antihistamines can be deadly. In February, the FDA issued a warning that the anti-allergy drug Hismanal (astemizole) can cause an irregular heartbeat—and possible cardiac arrest—if taken with protease inhibitors. Downing Hismanal along with grapefruit juice, antidepressants (such as Prozac) or the antibiotic Biaxin can do the same.

Reports of scary antihistamine interactions have surfaced ever since protease inhibitors were first prescribed—Seldane was even pulled off the market—but otherwise the FDA has been largely silent until now. In response to the red flag, Hismanal’s maker, Janssen Pharmaceutica, beefed up the antihistamine’s warning label. As always, read it carefully before beginning treatment. Claritin and Allegra (the new, safer Seldane) are alternatives for runny noses and itchy eyes, but their potential for protease interactions is still being investigated. Until speaking with your doctor, pack a box of tissues.

If You Buy One Book...

The HIV Wellness Sourcebook

The intricacies of Western medicine are tough enough for most PWAs to wrap their collective heads around, but add the Chinese variety and decision making becomes doubly daunting. Fortunately, The HIV Wellness Sourcebook (Henry Holt & Co.) can help the befuddled make both ends meet. Misha Cohen, a renowned complementary medicine clinician and researcher, outlines a comprehensive treatment program for HIV and its various pitfalls, including such infections as cryptosporidiosis and thrush, and quality-of-life destroyers ranging from diarrhea to depression. Cohen’s advice is especially valuable when it comes to tips on diet, exercise, acupressure and other self-care tools. Following a concise primer in Chinese medicine, Cohen details the most effective ways one can merge and get the most out of Chinese and Western therapies. This book is a must for anyone who won’t settle for less than the best of both worlds.—Bo Young

With anti-HIV drugs, it’s all a matter of class

With the ever-expanding market of drugs that attack HIV, and a smorgasbord-style approach to cocktail mixing, it’s more important than ever to appreciate differences in class. That is, which category (based on which HIV enzyme it targets) is a particular med a member of? And how many options do you have left in each?

Antiretrovirals—the whole kit and kaboodle of therapies that can stop a retrovirus such as HIV from reproducing; sometimes mistakenly used to refer only to “nukes”; the first class of antiretrovirals to get FDA approval.

Nucleoside-analogue reverse-transcriptase inhibitors (“RTIs,” or “nukes”)—the original antiretrovirals (AZT, ddI, ddC, 3TC, d4T); they contain a defective version of a natural nucleoside, which HIV’s reverse-transcriptase enzyme uses to make faulty DNA.

Non-nucleoside reverse transcriptase inhibitors (“NNRTIs” or “non-nukes”)—a new class of HIV zappers (e.g., Viramune, Rescriptor) that, like the nukes, target HIV’s reverse-transcriptase enzyme, not by “tricking” it, but by binding directly to it.

Protease inhibitors—the antiretroviral class of ’96 and beyond (Crixivan, Norvir, Fortovase, Viracept); they lock onto and block HIV’s protease enzyme—a sort of chemical pair of scissors that insidiously snips out proteins to make new virus.

“Multiple nutritional abnormalities occur early in the course of HIV infection and appear to facilitate disease progression.”
—Marianna Baum, PhD. Assistant Dean, University of Miami School of Medicine

“The failure of physicians and dietitians to recommend micronutrient supplementation to people with HIV is tantamount to malpractice.”
—Chester Myers, PhD. Biophysical chemist and nutritional researcher, Toronto, Canada

[Go to top]

Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Did you participate in an event for National Black HIV/AIDS Awareness Day 2016?


more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.